2CUREX AB |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.336 SEK | +5.00% |
|
-30.58% | -83.28% |
| Feb. 29 | 2curex AB Elects Grith Hagel as a New Board Member | CI |
| Feb. 22 | 2cureX AB Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2021 | 7.39M 678K | Sales 2022 | 3.37M 309K | Capitalization | 143M 13.16M |
|---|---|---|---|---|---|
| Net income 2021 | -18M -1.65M | Net income 2022 | -29M -2.66M | EV / Sales 2021 | 29.9 x |
| Net cash position 2021 | 72.94M 6.69M | Net cash position 2022 | 44.89M 4.12M | EV / Sales 2022 | 29.3 x |
| P/E ratio 2021 |
-14.6
x | P/E ratio 2022 |
-4.81
x | Employees | 14 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 42.42% |
More Fundamentals
* Assessed data
More news
Latest transcript on 2cureX AB
More press releases
| 1 day | +5.00% | ||
| 1 week | -30.58% | ||
| Current month | -26.32% | ||
| 1 month | -32.80% | ||
| 3 months | -77.60% | ||
| 6 months | -86.82% | ||
| Current year | -83.28% |
1 week
0.20
0.58
1 month
0.200.60
Current year
0.202.79
1 year
0.207.28
3 years
0.2024.95
5 years
0.2031.50
10 years
0.2031.50
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 48 | 21-01-31 | |
Grith Hagel
FOU | Founder | 65 | 05-12-31 |
Ole Thastrup
FOU | Founder | 71 | 05-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ole Thastrup
FOU | Founder | 71 | 05-12-31 |
| Chairman | - | Nov. 13 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-08 | 0.336 | +5.00% | 10 917 |
| 24-05-07 | 0.32 | -18.16% | 491,766 |
| 24-05-06 | 0.391 | -3.22% | 60,868 |
| 24-05-03 | 0.404 | -16.53% | 23,791 |
| 24-05-02 | 0.484 | +6.14% | 66,937 |
Delayed Quote Nasdaq Stockholm, May 08, 2024 at 06:28 am EDT
More quotes
2cureX AB is a Sweden-based company engaged in the biotechnology sector. The Company focuses on the research and development of diagnostic substances to select treatment for cancer patients. The Company's product candidate, IndiTreat - CRC, aims at optimizing medical treatment for the colorectal cancer patients. Through IndiTreat - CRC, healthcare professionals collect a tumor sample from patients to create a number of three-dimensional micro tumors in order to test available chemotherapies and experimental treatments. The Company's product pipeline includes also IndiTreat - OVA, targeting ovarian cancer treatment, and IndiTreat - KDN, focusing on kidney cancer treatment. It operates through 2cureX A/S.
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -83.28% | 521K | |
| -16.96% | 11.29B | |
| -30.43% | 2.29B | |
| -11.81% | 2.23B | |
| -23.56% | 1.61B | |
| +36.79% | 1.19B | |
| -3.28% | 752M | |
| -12.67% | 545M | |
| -36.53% | 458M | |
| +13.72% | 338M |
- Stock Market
- Equities
- 2CUREX Stock